Biodexa Pharmaceuticals Plc (BDRX) Financial Statements
Biodexa Pharmaceuticals Plc (BDRX) files with the U.S. Securities and Exchange Commission under CIK 0001643918. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Net Income
- -6.38 million GBP
- Total Assets
- 18.18 million GBP
- Net Cash from Operations
- -5.59 million GBP
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Mar 27, 2026. Source: SEC filings (EDGAR XBRL). Amounts in GBP.
Open the full financial statements for BDRX in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History